Pre-Conference Program

Monday, November 9, 2020

Immunotherapy Resistance and Failure
9 a.m.–3:15 p.m. EST

Organizers:
Kald Abdallah, MD, PhD – Bristol Myers Squibb
Edward Cha, MD, PhD – Genentech
Jennifer Gansert, MD, PhD - Amgen
Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
Giovanni Melillo, MD - AstraZeneca
Eric H. Rubin, MD – Merck

Session I: Defining Immune Checkpoint Inhibitor Resistance

9–9:05 a.m. Introduction
   Edward Cha, MD, PhD - Genentech

9:05–9:35 a.m. Definitions of Resistance and Gaps in Current Understanding
   Ryan J. Sullivan, MD - Massachusetts General Hospital

9:35–9:55 a.m. Mechanisms of Resistance and Possible New Combinations for Overcoming Them
   Paolo A. Acierto, MD - Istituto Nazionale Tumori IRCCS Fondazione Pascale

9:55–10:15 a.m. Immunotherapy Primary and Acquired Resistance
   Antoni Ribas, MD, PhD – University of California Los Angeles

10:15–10:30 a.m. Break

Session II: Primary Resistance

10:35–10:55 a.m. Approaches to Address Primary Resistance
   Siwen Hu-Lieskovan MD, PhD - Huntsman Cancer Institute, University of Utah

10:55–11:20 a.m. Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance
   Suzanne L. Topalian, MD - Johns Hopkins University School of Medicine

11:20–11:35 a.m. Coupled scRNA-seq and Intracellular Protein Activity Reveals Immune Suppressive Role of TREM2 in Cancer
   Yonatan Katzenelenbogen, B.Sc - Weizmann Institute of Science

11:35–11:50 a.m. -MHC-I and -II Expression Levels on Tumor cells and T cell Response to Immunotherapy in B78 Murine Melanoma Model
   Amy K. Erbe, PhD - University of Wisconsin

11:50–12:20 p.m. Break

Session III: Secondary/Acquired Resistance
12:20–12:45 p.m.  **Approaches to Address Acquired Resistance**  
Kevin J. Harrington, PhD, MD - *The Institute of Cancer Research*

12:45–1:00 p.m.  **Overcoming Acquired Resistance in anti-PD-1 Therapy by Simultaneously Depleting Tumor and All Major Types of Immunosuppressive cells**  
Yong Lu, PhD - *Wake Forest School of Medicine*

1:00–1:15 p.m.  **Preclinical Antitumor Activity of OncoVEXmGM-CSF in Combination with PD-1/PD-L1 Inhibitors in PD-L1 Resistant Mouse Models Supports the MASTERKEY-115 Study**  
Jing Qing, PhD - *Amgen Inc.*

1:15–1:30 p.m.  **Break**

**Session IV: Therapeutic Strategies for Patients with Resistant Disease**

1:30–1:45 p.m.  **Assessment of Circulating Tumor DNA (ctDNA) and Plasma Microsatellite Instability (MSI) during PD-1 Blockade**  
Pashtoon M. Kasi, MD, MS - *University of Iowa*

1:45–2:00 p.m.  **Radiological Dynamics and Resistance Types in Patients with Advanced Melanoma Treated with anti-PD-1 Monotherapy**  
Xue Bai, MD - *Peking University Cancer Hospital & MGH*

2:00–2:15 p.m.  **Precision Microbiome Mapping Identifies a Microbiome Signature Predictive of Immune Checkpoint Inhibitor Response Across Multiple Research Study Cohorts**  
Matthew J. Robinson, PhD - *Microbiota*

2:15–2:40 p.m.  **Regulatory Considerations**  
Marc Theoret, MD – *U.S. Food and Drug Administration, OHOP*

2:40–3:10 p.m.  **Panel Discussion**  
*Moderators:* Jennifer Gansert, MD, PhD – *Amgen*  
Israel Lowy, MD, PhD - *Regeneron Pharmaceuticals*  
*Panelists:*  
All Speakers

3:10–3:15 p.m.  **Closing Remarks**  
Israel Lowy, MD, PhD - *Regeneron Pharmaceuticals*

**Workshop on Engineering Immune Cells for Cancer Therapy**

9 a.m.–2:55 p.m. EST

**Organizers:**  
Christine Brown, PhD – *City of Hope*  
Katayoun Rezvani, MD, PhD – *The University of Texas MD Anderson Cancer Center*  
Marco Ruella, MD – *University of Pennsylvania*

**Session I: Advances in Adoptive T cell Therapy for Cancer: TILs and TCRs**

9–9:05 a.m.  **Introduction**  
Katayoun Rezvani, MD, PhD - *The University of Texas MD Anderson Cancer Center*

9:05–9:25 a.m.  **Cellular Immunotherapy for Metastatic Cancers**  
Steven A. Rosenberg, MD, PhD - *National Cancer Institute, National Institutes of Health*
9:25–9:45 a.m.  **Adoptive Therapy Utilizing TILs**  
John Haanen, MD, PhD - *Netherlands Cancer Institute*

9:45–10:05 a.m.  **Endogenous T cell Therapy for Solid Tumors Malignancies**  
Cassian Yee, MD - *The University of Texas MD Anderson Cancer Center*

10:05–10:20 a.m.  **Session I Panel Discussion - Session I Speakers**

10:20–10:35 a.m.  **Break**

**Session II: Novel Approaches to Enhance CAR T cell Therapy**

10:35–10:55 a.m.  **Next-generation CARS for blood cancers**  
Michael Hudecek, MD - *University of Wuerzburg*

10:55–11:15 a.m.  **Advancing Immunotherapy Platforms for the Treatment of Solid Tumors**  
Saul Priceman, PhD - *City of Hope*

11:15–11:35 a.m.  **Understanding Resistance to CAR T-cell Therapy to Develop Next-generation Immunotherapies**  
Marco Ruella, MD - *University of Pennsylvania*

11:35–11:50 a.m.  **Session II Panel Discussion - Session II Speakers**

11:50 a.m.–12:05 p.m.  **Break**

**Session III: CAR-Based Strategies Beyond T Lymphocytes**

12:05–12:25 p.m.  **CAR NK cells for the Immunotherapy of Cancer**  
Katy Rezvani, MD, PhD - *The University of Texas MD Anderson Cancer Center*

12:25–12:45 p.m.  **The Development of CAR Macrophages and Monocytes for Cancer Immunotherapy**  
Michael Klichinsky, PharmD, PhD - *Carisma Therapeutics*

12:45–1:05 p.m.  **Engineering B cells to Produce Therapeutic Antibodies**  
Justin Taylor, PhD - *Fred Hutchinson Cancer Research Center*

1:05–1:20 p.m.  **Session III Panel Discussion - Session III Speakers**

1:20–1:35 p.m.  **Break**

**Session IV: Integration of Novel Technologies for CAR Therapy and their Translation to the Clinic**

1:35–1:55 p.m.  **The Evolving Process of Clinical CAR T Cell Manufacturing in the Academic Setting**  
Isabelle Riviere, PhD - *Memorial Sloan Kettering Cancer Center*

1:55–2:15 p.m.  **Allogeneic CAR T therapy for Cancer**  
Barbra J. Sasu, PhD - *Allogene Therapeutics*

2:15–2:35 p.m.  **Corona Madness: Flattening the Curve with CAR T**  
Carl H. June, MD - *University of Pennsylvania*

2:35–2:50 p.m.  **Session IV Panel Discussion - Session IV Speakers**
Pre-Conference Program

Tuesday, November 10, 2020

7:30–8:30 a.m. EST
Sponsored Symposia: Medscape: A Deep Dive Into Immunotherapy in Advanced Endometrial Cancer

World Immunotherapy Council’s Virtual Young Investigator Session
8–9 a.m. EST

Organizers:
Bernard A. Fox, PhD - Providence Cancer Institute
Tanja D. de Gruijl, PhD - VU University Amsterdam

8–8:05 a.m. Introduction
Bernard A. Fox, PhD - Providence Cancer Institute

8:05–8:15 a.m. A combination of functional biomarkers improves identification of the tumor-specific reactive T cell repertoire
Arianna Draghi - Karolinska University Hospital

8:15–8:25 a.m. Deep immune profiling of SARS-CoV-2 associated immune microenvironment in cancer tissues from recovered COVID-19 patients
Denise Goh, BBiomedSc (Hons) - Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore

8:25–8:30 a.m. Expert Discussant
Tanja D. de Gruijl, PhD - VU University Amsterdam

8:30–8:40 a.m. Anti-LunX targeting therapy for lung cancer
Xiaohu Zheng - University of Science and Technology of China

8:40–8:50 a.m. Identification of tumor antigen-specific T cells in the peripheral blood of colorectal cancer patients
Emilie Picard, PhD - Health Sciences North/Horizon Sante Nord

8:50–8:55 a.m. Expert Discussant
Bernard A. Fox, PhD - Providence Cancer Institute

8:55–9 a.m. Closing Remarks
Bernard A. Fox, PhD - Providence Cancer Institute

Grant Writing Workshop
9–11:45 a.m. EST

Organizers:
Grey Wilkinson, PhD – Oncolytics Biotech Inc.
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School
Chair Claire Vanpouille-Box, PhD – Weill Cornell Medicine
David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center

9–9:05 a.m. Welcome Remarks
Claire Vanpouille-Box, PhD – Weill Medical College of Cornell University

9:05–9:30 a.m. Overview of Grant Opportunities and Principles of Grant Writing
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

9:30–9:55 a.m. K Awards and R01 Grants
William Matsui, MD – University of Texas at Austin

9:55–10:30 a.m. How to Write a Specific Aims Page
Thomas Gajewski, MD, PhD – University of Chicago

10:30–10:45 a.m. Panel Discussion
Moderator:
David Aggen, MD, PhD – Memorial Sloan Kettering Cancer Center
Panelists:
William Matsui, MD – University of Texas at Austin
Thomas Gajewski, MD, PhD – University of Chicago
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health

10:45–11:10 a.m. Mock Study Section
Moderator:
Zhang-Zhi Hu, MD - National Institute of Health
Panelists:
Scientific Review Officer - Malgorzata Klauzinska, PhD – National Institutes of Health
Chair - Thomas Gajewski, PhD – University of Chicago
Primary Reviewer - Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute
Secondary Reviewer - William Matsui, MD – University of Texas at Austin
Third Reviewer – Robyn Gartrell, MD – Columbia University/New York Presbyterian
Reader - Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

11:10–11:30 a.m. What Happens After the Study Section?
Malgorzata Klauzinska, PhD – National Institutes of Health

11:30–11:40 a.m. Panel Discussion
Moderator:
Grey Wilkinson, PhD – Oncolytics Biotech Inc.
Panelists:
William Matsui, MD – University of Texas at Austin
Thomas Gajewski, PhD – University of Chicago
Pawel Kalinski, PhD – Roswell Park Comprehensive Cancer Institute
Malgorzata Klauzinska, PhD – National Institutes of Health
Zhang-Zhi Hu, MD - National Institute of Health

11:40–11:45 a.m. Closing Remarks
Olivia Rongze Lu, PhD – University of Texas at Austin, Dell Medical School

Primer on Tumor Immunology and Cancer Immunotherapy™
9 a.m.–4 p.m. EST

Organizers:
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
Session I: Generating Anti-Tumor Immunity

9–9:05 a.m.  Introduction  
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

9:05–9:35 a.m.  The Adaptive Immune Response  
Jonathan D. Powell, MD, PhD – Johns Hopkins University School of Medicine

9:35–10 a.m.  Antigen Presenting Cells  
Nina Bhardwaj, MD, PhD - The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai

10–10:25 a.m.  Myeloid-derived Suppressor Cells as Negative Regulators of Immune Responses in Cancer  
Dmitry I. Gabrilovich, MD, PhD – AstraZeneca

10:25–10:40 a.m.  Session I Panel Discussion - Session I Speakers

10:40–10:55 a.m.  Break

Session II: Approaches to Immunotherapy I

10:55–11 a.m.  Introduction  
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

11–11:25 a.m.  T cell Checkpoint Blockade/Costimulation  
James P. Allison, PhD - University of Texas MD Anderson Cancer Center

11:25–11:50 a.m.  Cancer Vaccines  
Ugur Sahin, MD – BioNTech Group

11:50 a.m.–12:15 p.m.  The Suppressive Yin Versus Pro-Inflammatory Yang of the Tumor Myeloid Stroma  
Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center

12:15–12:30 p.m.  Session II Panel Discussion - Session II Speakers

12:30–12:50 p.m.  Break

Session III: Approaches to Immunotherapy II

12:50–12:55 p.m.  Introduction  
Yvonne Saenger, MD – Columbia University Irving Medical Center

12:55–1:20 p.m.  Be all that you can B: Imprinting an Antitumor T cell Army  
Chrystal M. Paulos, PhD – Emory University

1:20–1:45 p.m.  Immunometabolism and its Potential to Modify the Tumor Microenvironment  
Greg M. Delgoffe, PhD – University of Pittsburgh

1:45–2:10 p.m.  Mobilizing the Immune System with Bispecific Antibodies  
John R. Desjarlais, PhD – Xencor, Inc
2:10–2:25  Session III Panel Discussion - Session III Speakers
2:25–2:40  Break

Session IV: Clinical Practice of Immunotherapy
2:40–2:45p.m.  Introduction
Yvonne Saenger, MD – Columbia University Irving Medical Center
2:45–3:10  Immune Biomarkers to Guide Clinical Care
Yvonne Saenger, MD – Columbia University Irving Medical Center
3:10–3:35  Immune Related Adverse Events
Michael A. Postow, MD – Memorial Sloan Kettering Cancer Center
3:35–3:50  Session IV Panel Discussion - Session IV Speakers
3:50–4 p.m.  Closing Remarks
Yvonne Saenger, MD – Columbia University Irving Medical Center

35th Anniversary Annual Meeting

Wednesday, Nov. 11, 2020

8–8:30 a.m. EST  Sponsored Symposia: Natera: Deep Dive into the Clinical Utility of Personalized MRD Monitoring

Anniversary Award Ceremony
8:30–9 a.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine
8:30–9 a.m.  Introduction
Mario Sznol, MD – Yale School of Medicine
Public Service Award
Patient Advocacy Award

Session 100: Presidential Welcome & Rosenberg Award Announcement
9–9:30 a.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine
9–9:30 a.m.  Presidential Welcome
Mario Sznol, MD – Yale School of Medicine

Session 101: Richard V. Smalley, MD Memorial Award and Lectureship: Discovery, Development, and Application of the PD-1/PD-L1; B7-H1 Antagonist Antibodies
9:30–11 a.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine

9:30–10 a.m. The PD-L1/PD-1 Pathway: Discovery and New Insights
Gordon Freeman, PhD – Dana-Farber Cancer Institute

10–10:30 a.m. Why were we interested in immunity within the tumor microenvironment in the 1990s?
Lieiping Chen, MD, PhD – Yale School of Medicine

10:30–11 a.m. Discovery of New IO Targets and Mechanisms Leveraging CRISPR
Arlene Sharpe, MD, PhD – Harvard Medical School

Break
11–11:15 a.m.

Session 102: Combinatorial Therapies
11:15 a.m.–1:10 p.m. EST
Co-Chairs:
Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center
Silvia Formenti, MD – Weill Cornell Medicine

11:15–11:20 a.m. Introduction

11:20–11:30 a.m. (470) Targeting Pan-Tumor Associated Antigen B7H3 via Combination of Tri-specific Killer Engager and Off-the-shelf NK Cell Therapy Enhances Specificity and Function Against a Broad Range of Solid Tumors
Nicholas Zorko, MD, PhD – University of Minnesota

11:30–11:40 a.m. (446) Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition
Peter Joyce, PhD - Grey Wolf Therapeutics Limited

11:40–11:50 a.m. (362) A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
James Spicer, PhD, FRCP - King's College London

11:50 a.m.–12:05 p.m. Expert Discussant
Charlotte E. Ariyan, MD, PhD – Memorial Sloan Kettering Cancer Center

12:05–12:15 p.m. Q&A

12:15–12:25 p.m. (200) NBCTXR3 nanoparticle with immunoradiation improves survival and generates long-term anti-tumor memory in an anti-PD1 resistant Murine Lung Cancer Model
Yun Hu, PhD - The University of Texas MD Anderson Cancer Center

12:25–12:35 p.m. (368) REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

12:35–12:45 p.m. (386) Phase I/II first-in-human study of HEK-NIZ2985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors
John Thompson, MD - University of Washington Seattle Cancer Care

12:45–1 p.m. Expert Discussant
Chandan Guha, MB, BS, PhD – Montefiore Medical Center
1–1:10 p.m.  Q&A

Break
1:10–1:30 p.m.

Virtual Exhibit Hall & Poster Hall Hours
1–2 p.m.

Concurrent Rapid Oral Abstract Presentation Session 103: Basic Research
1:30–2 p.m. EST
Co-Chairs:
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts Institute of Technology

1:30–1:38 p.m.  (90) Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway
Jonathan Boiarsky, BA - Icahn School of Medicine at Mount Sinai

1:38–1:46 p.m.  (209) Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasone’s detrimental effects on immune checkpoint blockade in glioblastoma cancer
Bryan Iorgulescu, MD - Dana-Farber Cancer Institute

1:46–1:54 p.m.  (472) ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma
Natasha D. Sheybani, PhD - University of Virginia

1:54–2 p.m.  Q&A

Concurrent Rapid Oral Abstract Presentation Session 104: Clinical
1:30–2 p.m. EST
Co-Chairs:
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina

1:30–1:38 p.m.  (420) Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Adi Diab, MD - The University of Texas MD Anderson Cancer Center

1:38–1:46 p.m.  (547) Identification of the immune landscape in penile squamous cell carcinoma using multiplex immunofluorescence and spatial image analysis
Rosanna N. Lazcano Segura, MD - The University of Texas MD Anderson Cancer Center

1:46–1:54 p.m.  (455) Impact of EphB4 and PD-1 treatment on immune infiltrate in advanced bladder cancer
Sarmad Sadeghi, MD - Keck School of Medicine of USC

1:54–2 p.m.  Q&A

Session 105: Integrating Radiation and Immunotherapy: New Products, Challenges, and Opportunities for Industry-Academic Collaborations
2–3:30 p.m. EST
Co-Chairs:
Zachary Morris, MD, PhD – University of Wisconsin, Madison
Andrew Sikora, MD, PhD – The University of Texas MD Anderson Cancer Center

2–2:05 p.m.  Introduction
Andrew Sikora, MD, PhD – The University of Texas MD Anderson Cancer Center

2:05–2:20 p.m.  The Immuno-Radiobiology of Radiation Therapy
Zachary Morris, MD, PhD – University of Wisconsin, Madison

2:20–2:35 p.m.  **Optimal Sequencing of Radiation and Immunotherapy**
Silvia Formenti, MD – Weill Cornell Medicine

2:35–2:50 p.m.  **Design of Clinical Trials Integrating Radiation and Immunotherapy**
Jonathan D. Schoenfeld, MD, MPhil, MPH – Harvard University

2:50–3 p.m.  **NCI SBIR Opportunities**
Kory Hallet, PhD – NCI SBIR Development Center

3–3:25 p.m.  **Best Practices and Future Perspectives for Integrating Radiation and Immunotherapy Panel Discussion**
Mansoor Ahmed, PhD – National Cancer Institute
Michael Bassetti, MD, PhD – University of Wisconsin-Madison
Sue L. Currie, PhD – Nektar Therapeutics
Sandra Demaria, MD – Weill Cornell Medicine
Silvia Formenti, MD – Weill Cornell Medicine
Kory Hallet, PhD – NCI SBIR Development Center
Tibor Keler, PhD – Celldex Therapeutics, Inc.
Sophia Pfister, PhD – Varian
Jonathan D. Schoenfeld, MD, MPhil, MPH – Harvard University
Andrew Sharabi, MD, PhD – Moores Cancer Center
Kristina H. Young, MD, PhD – Earle A. Chiles Research Institute
Samir Khleif, MD – Georgetown University Medical Center
Chiayeng Wang, PhD – National Cancer Institute, NIH
Paul Sondel, MD, PhD – University of Wisconsin-Madison

3:25–3:30 p.m.  **Closing Remarks**

**Break**
3:30–3:45 p.m.

**Concurrent Session 106: Developing Cellular Therapies for Solid Cancers**
3:45–5:15 p.m. EST

**Co-Chairs:**
Stephanie L. Goff, MD, FACS – National Cancer Institute
Avery Posey, PhD – University of Pennsylvania School of Medicine

3:45–4:05 p.m.  **TILs**
Michal Besser, PhD – The Sheba Medical Center at Tel Hashomer

4:05–4:25 p.m.  **TCR Cells**
James C. Yang, MD – National Cancer Institute

4:25–4:45 p.m.  **CAR for Solid Tumors**
Avery Posey, PhD – University of Pennsylvania School of Medicine

4:45–5:05 p.m.  **NKT Cells**
Andras A. Heczey, MD – Baylor College of Medicine

5:05–5:15 p.m. (122) **Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model**
Amanda N. Lisby, MS - Thomas Jefferson University

**Concurrent Session 107: Neoadjuvant Immunotherapies**
3:45–5:15 EST
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Janis M. Taube, MD, MSc – Johns Hopkins School of Medicine

3:45–4:05 p.m. Pan-Tumor Pathologic Response Assessment
Janis M. Taube, MD, MSc – Johns Hopkins University School of Medicine

4:05–4:25 p.m. Neoadjuvant Breast Cancer
Elizabeth A. Mittendorf, MD, PhD – Dana-Farber Cancer Institute

4:25–4:45 p.m. Bladder Cancer (Treme/Durva)
Jianjun Gao, MD, PhD – The University of Texas MD Anderson Cancer Center

4:45–5 p.m. (432) 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma
Reinhard Dummer, MD – University Hospital of Zurich

5–5:15 p.m. (264) Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma
Raquel Deering, PhD – Regeneron Pharmaceuticals, Inc.

Concurrent Session 108: Diet and Microbiome
3:45–5:15 p.m. EST
Co-Chairs:
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai
Laurence Zitvogel, MD, PhD – Institut Gustave Roussy

3:45–4 p.m. Introduction into Microbiome & Diet
Jeremiah Faith, PhD – Icahn Institute for Data Science and Genomic Technology at Mt. Sinai

4–4:20 p.m. Micronutrients with Immunostimulatory Properties
Guido Kroemer, MD, PhD – Institut Gustave Roussy

4:20–4:40 p.m. Linking the gut microbiome to cancer immunotherapy response
Meriem Messaoudene, PhD – CRCHUM, Bertrand Routy Lab

4:45–5:05 p.m. Diet, the microbiome, and immune response: From observation to intervention
Jennifer L. McCuade, MD – The University of Texas MD Anderson Cancer Center

5:05–5:15 p.m. (672) Identification of microbial-derived HLA-bound peptides in melanoma
Adi Nagler, MSc - Weizmann

Concurrent Session 109: Innate Immunity: The Next Generation of targets for Anti-Cancer Immunotherapy
3:45–5:15 p.m. EST
Co-Chairs:
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center

3:45–4:05 p.m. Harnessing Tumor Associated Macrophages for Anti-Cancer Therapy
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

4:05–4:25 p.m. Gamma-delta T cells
Adrian Hayday, FRS, F MedSci – Gamma Delta Therapeutics

4:25–4:45 p.m. NK cells
Andreas Lundqvist, PhD – Karolinska Institutet
4:45–5 p.m.  (531) AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies  
Nancy D. Marin, PhD - Washington University, St. Louis

5–5:15 p.m.  (539) High dimensional analysis of the human lymph node during melanoma progression reveals shifts in myeloid content that relate to differential T cell content  
Anastasia Prokopi, PhD - Amsterdam, UMC

Virtual Exhibit Hall & Poster Hall Hours
5–6 p.m.

Session 110: E-Poster Viewing Session
5:15–5:45 p.m. EST

Session 111: The Surgeon’s Impact on Tumor Immunotherapy: Recent Achievements and Future Promise
5:30–6:30 p.m. EST

Co-Chairs:
Howard L. Kaufman, MD, FACS – Immuneering Corporation  
Brian R. Gastman, MD – Cleveland Clinic Cancer Center

5:30–5:35 p.m.  Introduction  
Brian R. Gastman, MD – Cleveland Clinic Cancer Center

5:35–5:45 p.m.  Oncolytic Viruses: The Importance of Surgical Input  
Howard L. Kaufman, MD, FACS – Immuneering Corporation

5:45–5:50 p.m.  (274) Tumoral and peripheral immunophenotype of refractory vs relapse to PD-(L)1 blockade in patients with advanced Non-Small Cell Lung Cancer  
Maria L. Ascierto, PhD – AstraZeneca

5:50–5:55 p.m.  (277) Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy  
Boris Sepesi, MD - The University of Texas MD Anderson Cancer Center

5:55–6:00 p.m.  (303) Phase II Trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (IT) CMP-001 in High-Risk Resectable Melanoma (Neo-C-Nivo): Final Results  
Diwakar Davar, MD – UPMC Hillman Cancer Center

6–6:05 p.m.  (449) Neoadjuvant cyclic dinucleotides combined with interleukin-2 and anti-PD-1 antibody limit lung metastasis of orthotopic breast tumors through prolonged NK cell activation  
Lauren Milling, BS – Massachusetts Institute of Technology

6:05–6:10 p.m.  (254) CTLA-4 blockade promotes Treg glucose metabolism and reduces Treg functional stability in glycolysis-defective tumors  
Roberta Zappasodi, PhD - Memorial Sloan Kettering Cancer Center

6:10–6:20 p.m.  Expert Discussant  
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health

6:20–6:30 p.m.  Q&A

Break
6:30–7 p.m.

Replay Session with Live Q&A: Rapid Oral Abstracts: Basic Research
7–8 p.m. EST

**Co-Chairs:**
Sarah Church, PhD – NanoString Technologies
Brendan Horton, PhD – Massachusetts Institute of Technology

Replay Session with Live Q&A: Rapid Oral Abstracts - Clinical
7–8 p.m. EST

**Co-Chairs:**
Ravi Patel, MD, PhD – University of Pittsburgh
Jessica Thaxton, PhD, MSCR – Medical University of South Carolina

---

**35th Anniversary Annual Meeting**

**Thursday, Nov. 12, 2020**

7:30-8:30 a.m. **Sponsored Symposia: OncoSec-DNA Plasmid-based IL-12 Delivered Intratumoral Electroporation: Achieving Meaningful Tumor Responses While Avoiding Systemic Toxicities**

**Anniversary Award Ceremony**
8:30–9 a.m. EST

**Chair:**
Mario Sznol, MD – Yale School of Medicine

8:30-8:32 a.m. **Introduction**
Mario Sznol, MD – Yale School of Medicine

8:32-8:41 a.m. **Extraordinary Service Awards**

8:42-8:44 a.m. **Introduction**
Mario Sznol, MD – Yale School of Medicine

8:44-8:54 a.m. **Visionary/Legacy Award**

**Session 201: Keynote Address**
9–9:50 a.m. EST

**Chair:**
Mario Sznol, MD – Yale School of Medicine

9–9:05 a.m. **Introduction**
Mario Sznol, MD – Yale School of Medicine

9:05–9:45 a.m. **Turning Immunologically Quiescent Tumors into Immune Responsive Cancers**
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

9:45–9:50 a.m. **Q&A**
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

**Break**
9:50–10:05 a.m.

**Session 201: Exploring the Tumor Microenvironment**
10:05–noon EST
**Co-Chairs:**
Vincenzo Bronte, MD – University of Verona
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

10:05–10:15 a.m. **Introduction**

10:15–10:40 a.m. **Stromal Cells in Health, Disease and Immunotherapy**
Shannon J. Turley, PhD – Genentech Inc.

10:40–11:05 **Exploring and Exploiting the Immune Landscape in Brain Cancers**
Johanna A. Joyce, PhD – University of Lausanne & Ludwig Institute for Cancer Research

11:05–11:30 a.m. **Investigating Genetic Control of the Tumor Microenvironment by Spatial Functional Genomics**
Brian D. Brown, PhD – Icahn School of Medicine at Mount Sinai

11:30–11:45 a.m. **(TJ210) TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy**
Jane Meng, PhD - I-Mab Biopharma

11:45 a.m.–noon **(Comparison of Two oHSV Vectors for the Treatment of Glioblastoma)**
Joseph Jackson, PhD - University of Pittsburgh

**Session 202: Late-Breaking Abstract Session**
Noon-12:30 p.m. EST
**Chair:**
Sandra Demaria, MD – Weill Cornell Medicine

Noon–12:15 p.m. **(Phenotypic Correlates of Adoptive Cell Therapy Response in Melanoma)**
Sri Krishna, PhD – National Cancer Institute

12:15–12:30 p.m. **(Pembrolizumab for Patients with Leptomeningeal Metastasis from Solid Tumors: Efficacy, Safety and Cerebrospinal Fluid Biomarkers)**
Jarushka Naidoo, MBBCH, MHS – Johns Hopkins Sidney Kimmel Cancer Center

**Break**
12:30–2 p.m.

**Concurrent Session 203: Rapid Oral Abstract Presentation: Basic Research**
12:50-1:20 p.m. EST
**Co-Chairs:**
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center
Spencer Wei, PhD – Spotlight Therapeutics

12:50–12:58 p.m. **(Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors)**
Paolo D.A. Vignali, BS — The University of Pittsburgh School of Medicine

12:58–1:06 p.m. **(CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity)**
Alvaro Teijeira - CIMA Pamplona

1:06–1:14 p.m. **(Regulatory T cell functional identity is sustained by a glucose:lactate axis that is exploited in the tumor microenvironment)**
McLane Watson, BS - University Of Pittsburgh

1:14–1:20 p.m. **Q&A**

**Concurrent Session 204: Rapid Oral Abstract Presentation: Clinical**
12:50 – 1:20 p.m. EST

**Co-Chairs:**
- Robyn Gartrell, MD, MS – Columbia University
- Saman Maleki, PhD – Western University

**12:50 – 12:58 p.m.**
(294) **CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: a phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody**
Michael D. Farwell, MD - University of Pennsylvania

**12:58 – 1:06 p.m.**
(588) **Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases**
Yannick S. Rakke, MD, MSc - Erasmus University Medical Center

**1:06 – 1:14 p.m.**
(31) **Dynamic change of PD-L1 expression on extracellular vesicles predicts response to immune-checkpoint inhibitors in non-small cell lung cancer patients**
Diego de Miguel Perez, PhD, MSc - University of Maryland

1:14 – 1:20 p.m. **Q&A**

**Session 205: Toxicities of Cancer Immunotherapies**
1:20 – 3:05 p.m. EST

**Co-Chairs:**
- Caroline Robert, MD, PhD – Institut Gustave Roussy
- Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

**1:20 – 1:45 p.m.** **Toxicities from ICI**
Caroline Robert, MD, PhD – Institut Gustave Roussy

**1:45 – 2:10 p.m.** **Factors Associated with Toxicities of CD19 CAR-T cell Immunotherapy**
Cameron J. Turtle, MBBS, PhD, FRACP – Fred Hutchinson Cancer Research Center

**2:10 – 2:35 p.m.** **CAR-T Studies**
Ansuman T. Satpathy, MD, PhD – Stanford

**2:35 – 2:50 p.m.** (653) **Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release**
Gabrielle Leclercq, MSc - Roche

**2:50 – 3:05 p.m.** (645) **Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis**
Nazli Dizman, MD - Yale New Haven Hospital

**Break**
3:05 – 3:20 p.m.

**Concurrent Session 206: Vaccines and Immunoprevention**
3:20 – 4:50 p.m. EST

**Co-Chairs:**
- Shizuko Sei, MD – National Cancer Institute
- Catherine J. Wu, MD – Dana-Farber Cancer Institute

**3:20 – 3:50 p.m.** **Personal Cancer Vaccines: on the Path to Effective Cancer Immunity**
Catherine J. Wu, MD – Dana-Farber Cancer Institute

**3:50 – 4:20 p.m.** **Cancer Vaccines for Lynch Syndrome Carrier**
Eduardo Vilar-Sanchez, MD, PhD – The University of Texas MD Anderson Cancer Center
4:20–4:35 p.m.  
(598) Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes  
Rana Falahat, PhD – Moffit Cancer Center

4:35–4:50 p.m.  
(612) Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells  
Kristen Radford, PhD – Mater Research Institute

Concurrent Session 207: Gene Editing  
3:20–4:50 p.m. EST  
Co-Chairs:  
Helen E. Heslop, MD – Baylor College of Medicine  
Carl H. June, MD – University of Pennsylvania

3:20–4:50 p.m.  
Panelists  
Matthew Porteus, MD, PhD – Stanford University  
Vijay Peddaredigari, MD – Tmunity  
Zhaohui Ye, PhD, PI Regulatory – FDA, Center for Biologics Evaluation and Research  
Chryystal Louis, MD, MPH – CRISPR Therapeutics

Concurrent Session 208: Bispecific Antibodies in Cancer Immunotherapy  
3:20–4:50 p.m. EST  
Co-Chairs:  
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.  
Mario Sznol, MD – Yale School of Medicine

3:20–3:40 p.m.  
Human Costimulatory Bispecifics Antibodies in Cancer Immunotherapy  
Dimitris Skokos, PhD – Regeneron Pharmaceuticals, Inc.

3:40–4 p.m.  
PD1-IL2v: A Next Generation, PD-1-targeted IL-2R Agonist for Cancer Immunotherapy  
Pablo Umana, PhD – Roche Glycart AG

4–4:15 p.m.  
(633) Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor  
Michelle H. Nelson, PhD – Aptevo Therapeutics

4:15–4:30 p.m.  
(632) HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors  
Jack Lin, PhD – Harpoon Therapeutics

4:30–4:45 p.m.  
(359) AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results  
Hossein Borghaei, MS, DO – Fox Chase Cancer Center

Concurrent Session 209: Immunometabolism and ICI Resistance  
3:20–4:50 p.m. EST  
Co-Chairs:  
Susan M. Kaech, PhD – Salk Institute  
Maxim N. Artyomov, PhD – Washington University School of Medicine in St. Louis

3:20–3:45 p.m.  
Metabolic Regulation of Anti-Tumor NK cells  
Susan M. Kaech, PhD – Salk Institute

3:45–4:10 p.m.  
Metabolic Processes that Affect Anti-Tumor Immune Responses  
Santosh Vardhana, MD, PhD – Memorial Sloan Kettering Cancer Center
35th Anniversary Annual Meeting

Friday, Nov. 13, 2020

SITC Membership Business Meeting
8–8:30 a.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine

Anniversary Award Ceremony
8:30–9 a.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine

8:30–8:32 a.m.  Introduction
Mario Sznol, MD – Yale School of Medicine

8:32–8:37 a.m.  Extraordinary Service to JITC Awards

8:37–8:47 a.m.  Collaboration Awards

8:47–8:51 a.m.  NCI Collaboration

8:51–9 a.m.  Closing
Session 300: 35th Anniversary Keynote: T cell Therapy of Cancer
9–9:50 a.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine

9–9:05 a.m.  Introduction
Mario Sznol, MD – Yale School of Medicine

9:05–9:45 a.m. T cell Therapy of Cancer
Helen E. Heslop, MD – Baylor College of Medicine

9:45–9:50 a.m.  Q&A

Break
9:50–10:05 a.m.

Session 301: Hot Topic Symposium: COVID-19 and Cancer
10:05–12:40 p.m. EST
Co-Chair:
Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Institute, Icahn School of Medicine at Mt Sinai

10:05–10:30 a.m. Infection/Immunology
Florian Krammer, PhD - Icahn School of Medicine at Mount Sinai

10:30–10:55 a.m. Infection in Cancer Patients Specifically
Elizabeth V. Robilotti, MD, MPH – Memorial Sloan Kettering Cancer Center

10:55–11:05 a.m. Break

11:05–11:15 a.m. Repurposing Cancer Immunotherapies for COVID
Paolo Ascierto , MD - Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale

11:15–11:25 a.m. Big Data and Informatics – Viral Sequencing and Epitope Identification
Benjamin Greenbaum, MD – Memorial Sloan Kettering Cancer Center

11:25–11:35 a.m. Big data and Informatics – Viral Sequencing and Epitope Identification
Marta Luksza, PhD– Icahn School of Medicine at Mount Sinai

11:35–11:55 a.m. Q&A

11:55–12:15 p.m. Panel Discussion: Immunotherapy and COVID Outcomes (ICIs) and Cancer Care in Pandemic
Jia Luo, MD - Memorial Sloan Kettering Cancer Center
Aljosja Rogiers, MD – Institute of Melanoma

12:15–12:25 p.m. (325) Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memorial B cells and memory T effector cells
Gerard Criner, MD – Temple University
Incidental finding of colorectal cancer in a COVID-19 patient, followed by deep profiling of SARS-CoV-2-associated immune landscape and tumour microenvironment
Chun Chau Lawrence Cheung, BA, MMedSc - Singapore General Hospital

Closing

Break
12:40–1 p.m. EST

Virtual Exhibit & Poster Hall Hours
12:30–1:30 p.m. EST

Session 302: Late-Breaking Abstract Session
1–1:30 p.m. EST
Chair:
Roberta Zappasodi, PhD – Weill Cornell Medicine

1–1:15 p.m. (795) A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Micheal Wagner, MD – University of Washington

1:15 – 1:30 p.m. (812) Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer
Lei Zheng, MD, PhD – Johns Hopkins University School of Medicine

Session 303: Presidential Session
1:30–2:55 p.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine

1:30–1:35 p.m. Introduction
Mario Sznol, MD – Yale School of Medicine

1:35–1:50 p.m. (528) Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b
Defne Bayik, PhD - Cleveland Clinic

1:50–2:05 p.m. (36) Molecular events regulating solid tumor cell responses to natural killer cells
Michal Sheffer, PhD - Dana-Farber Cancer Institute

2:05–2:15 p.m. Expert Discussant
Jeffrey Miller, MD – University of Minnesota

2:15–2:30 p.m. (629) Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody
Emily Hsiue, MD - Oncology

2:30–2:45 p.m. (465) Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection
Nils Rudqvist, PhD - The University of Texas MD Anderson Cancer Center

2:45–2:55 p.m. Expert Discussant
Robert H. Vonderheide, MD, Dphil – University of Pennsylvania Perelman School of Medicine
Break
2:55–3:10 p.m. EST

Concurrent Session 304: Novel Immunotherapies in Myeloid Malignancies
3:10–4:40 p.m. EST
Co-Chairs:
Naval Daver, MD – The University of Texas MD Anderson Cancer Center
Marcela V. Maus, MD, PhD – Massachusetts General Hospital

3:10–3:30 p.m.  CD47 Macrophage Checkpoint-Based Immunotherapy (Lymphomas, MDS, AML)
David Sallman, MD – Moffitt Cancer Center

3:30–3:50 p.m.  Bispecific Antibodies
Marion Subklewe, MD – University of Munich

3:50–4:10 p.m.  CAR T for AML
Elizabeth Budde, MD, PhD – City of Hope

4:10–4:40 p.m.  Emerging and personalized cellular therapy approaches for myeloid diseases
Marco L. Davila, MD, PhD – Moffitt Cancer Center

Concurrent Session 305: Reverse Translation for Clinical Trials
3:10–4:40 p.m. EST
Co-Chairs:
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Matthew D. Galsky, MD – Tisch Cancer Institute at Mount Sinai

3:10–3:30 p.m.  Rational Design of Tumor-Specific Therapeutic and Biomarker Strategies through Reverse Translational Studies
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center

3:30–3:50 p.m.  Clinical Trial Design Considerations to Facilitate Reverse Translation
Thomas Marron, MD, PhD – Icahn School of Medicine at Mount Sinai

3:50–4:10 p.m.  Identifying Novel Therapeutics Targets to Overcome Immune Checkpoint Blockade Resistance Through Reverse Translation
Sanjeev Mariathasan, PhD – Genentech

4:10–4:25 p.m.  (332) Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab
Keun-Wook Lee, MD, PhD – Seoul National University College of Medicine

4:25–4:40 p.m.  (352) Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
Ezra Cohen, MD – University of California San Diego

Concurrent Session 306: Engineering Immunity: Bimolecular and Genetic Approaches to Generating Novel Therapeutic Function
3:10–4:40 p.m. EST
Co-Chairs:
Yvonne Chen, PhD – University of California, Los Angeles
Kole T. Roybal, PhD – University of California, San Francisco

3:10–3:35 p.m.  Biomaterials – Basic Biology
Concurrent Session 307: B cells
3:10–4:40 p.m. EST

Co-Chairs:
Tullia C. Bruno, PhD – UPMC Hillman Cancer Center
Wolf H. Fridman, MD, PhD – Cordeliers Research Centre

3:10–3:30 p.m. B cells and Tertiary Lymphoid Structures as biomarkers for prognosis and immunotherapy
Wolf H. Fridman, MD, PhD – Cordeliers Research Centre

3:30–3:50 p.m. The Role of B cells and TLS in Immunotherapy Response
Jennifer Wargo, MD – The University of Texas MD Anderson Cancer Center

3:50–4:10 p.m. Targeting tertiary lymphoid structure heterogeneity and B cell function in non-small cell lung cancer patients
Tullia C. Bruno, PhD – UPMC Hillman Cancer Center

4:10–4:17 p.m. (536) Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer
Ayana Ruffin, MS – University of Pittsburgh

4:17–4:24 p.m. (167) B-cell-based vaccination elicit potent immunity against glioblastoma
Catalina Lee-Chang, PhD – Northwestern University

4:24–4:30 p.m. Expert Discussant
Brad Nelson, PhD – Deeley Research Centre at BC Cancer Agency

4:30–4:40 p.m. Q&A

Session 308: E-Poster Viewing Session
4:40–5:10 p.m. EST

Virtual Exhibit & Poster Hall Hours
4:30–5:30 p.m.

Break
5:10–7 p.m. EST

Replay Session with Live Q&A: Late-Breaking Abstracts
7–8 p.m. EST

Chair:
Roberta Zappasodi, PhD – Weill Cornell Medicine
35th Anniversary Annual Meeting

Saturday, Nov. 14, 2020

Anniversary Award Ceremony
8:30–9 a.m. EST
Chair:
Mario Sznol, MD – Yale School of Medicine
8:30–8:32 a.m. Introduction
Mario Sznol, MD – Yale School of Medicine
8:32–8:44 a.m. Team Science Award

Session 400: 35th Anniversary Session: Mechanistic Understandings and Misunderstandings
9–10:30 a.m. EST
Chair:
James P. Allison, PhD – The University of Texas MD Anderson Cancer Center
John Wherry, PhD – University of Pennsylvania
9–9:30 a.m. TBA
Ira Mellman, PhD – Genentech
9:30–10 a.m. TBA
John Wherry, PhD – University of Pennsylvania
10–10:30 a.m. TBA
Matthew Spitzer, PhD – University of California San Francisco

Break
10:30-10:45 a.m. EST

Session 401: Biomarkers and Big Data
10:45 a.m. –12:40 p.m. EST
Co-Chairs:
Michael Angelo, MD, PhD – Stanford University
Nir Hacohen, PhD – Broad Institute
10:45–10:55 a.m. Introduction
Nir Hacohen, PhD – Broad Institute
10:55–11:20 a.m. Spatial Analysis of Immune Responses in Tumors
Leeat Keren, PhD – Stanford University
11:20–11:45 a.m. Blood-Based Predictors of Tumor Immunity
Jane Grogan, PhD – ArsenalBio
11:45 a.m.–12:10 p.m. Capturing heterogeneity and the HLA-presented landscape in melanoma
Yardena Samuels, PhD – Weizmann Institute of Science
12:10–12:25 p.m. (62) Identify immune cell types and biomarkers associated with immune-related adverse events using single cell RNA sequencing
Jiamin Chen, PhD – Stanford University Medical School
12:25–12:40 p.m.  (21) Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
Michal Harel, PhD – Oncohost LTD

Break
12:40 – 1 p.m. EST

Virtual Exhibit & Poster Hall Hours
12:30 – 1:30 p.m. EST

Session 402: E-Poster Viewing Session
1–1:30 p.m. EST

Session 403: Poster Symposium
1:30 – 2:45 p.m. EST
Co-Chairs:
Niroshana Anandasabapathy, MD, PhD – Weill Cornell Medicine
Sangeeta Goswami, MD, PhD – The University of Texas MD Anderson Cancer Center

1:30 – 1:40 p.m.  (545) Tumor-specific cytolitic CD4 T cells mediate protective immunity against human cancer
Camilla Jandus, MD, PhD – University of Geneva

1:40 – 1:50 p.m.  (206) An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer
Elizabeth R. Stirling, MS – Wake Forest University

1:50 – 2 p.m.  (549) Characterizing Double Positive T cells in the Tumor Microenvironment: a tale of promiscuous cell fates
Sara Schad, BS – Memorial Sloan Kettering Cancer Center

2–2:10 p.m.  (152) Adoptive T cell therapy targeting somatic p53 mutations
Peter Kim, PhD – National Institute of Health

2:10–2:20 p.m.  (744) Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy
Hussein Abbas, MD, PhD – The University of Texas MD Anderson Cancer Center

2:20–2:30 p.m.  (248) Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing
Kartik Sehgal, MD – Dana-Farber Cancer Institute

2:30–2:45 p.m.  Q&A

Break
2:45–3 p.m. EST

Session 404: Next Generation Immunotherapy Combinations: Navigating FDA, Clinical Trial Design, Diagnostics and Novel Biomarkers
3–4:30 p.m. EST
Co-Chairs
Emily Hopewell, PhD, MT – Indiana University
Ke Liu, MD, PhD – Food and Drug Administration (FDA)
Jason Luke, MD, FACP – UPMC
Marc Theoret, MD – Food and Drug Administration (FDA), CDER, OHOP

3–3:05 p.m.  Welcome
Jason Luke, MD – UPMC Hillman Cancer Center
Navigating the Road to Developing and Pursuing Novel Cellular and Non-Cellular Combination Immunotherapy Clinical Trials: FDA Overview
Adnan A. Jaigirdar, MD, FACS – Food and Drug Administration

FDA Perspective on Areas of Research Needed in Advancing Neo-Adjuvant Immunotherapy Toward Clinical Practice
Nicole Drezner, MD – Food and Drug Administration

Difficulties and opportunities in developing cellular therapy and cancer therapeutics clinical trials: science and logistics for investigators
Cassian Yee, MD – The University of Texas MD Anderson Cancer Center

Improving patient selection in cellular therapy studies and neoadjuvant trials
Rodabe N. Amaria, MD – The University of Texas MD Anderson Cancer Center

Panel Discussion

Closing Remarks

On-Demand Session

Update Session: National Cancer Institute (NCI)
Norman E. Sharpless, MD – National Cancer Institute

Update Session: Food and Drug Administration (FDA)
Raj Puri, MD, PhD – U.S. Food and Drug Administration

Update Session: FDA Oncology Center of Excellence (FDA OCE)
Marc Theoret, MD – U.S. Food and Drug Administration, OHOP

Update Session: Cancer Immunotherapy Trials Network (CITN)
Martin A. Cheever, MD Fred - Hutchinson Cancer Research Center

Update Session: SITC Policy Committee
George J. Weiner, MD - University of Iowa, Holden Comprehensive Cancer Center

Update Session: Women in Cancer Immunotherapy Network (WIN)
Lisa H. Butterfield, PhD – Parker Institute for Cancer Immunotherapy

Update Session: International Neoadjuvant Melanoma Consortium (INMC)
Elizabeth M. Burton, MBA – The University of Texas MD Anderson Cancer Center